低酸素誘発のPRMT1乳酸化は,腫瘍転移におけるヴィメンチン・アルギニンの非対称性ディメチル化を誘発する
Jia Zhou1, Shuying Qiu1, Xia Yang2
1Department of Medical Oncology, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|August 30, 2025
まとめ
低酸素はタンパク質アルギニンメチルトランスフェラーゼ1 (PRMT1) の乳化を誘発し,その活性性を高め,ヴィメンチンを改変し,癌の転移を引き起こします. この低酸素- PRMT1- 酵素軸をターゲットにすることで,新種の抗転移戦略が提供されます.
科学分野:
- 腫瘍学
- 分子生物学
- 生物化学
背景:
- 転移は癌による死亡の主な原因であり,有効な治療法は限られている.
- ヒポキシア誘発のエピテリア・メゼンキマ移行 (EMT) は癌細胞の拡散を促します.
- EMTにおける細胞骨格の変化を制御する翻訳後の変更は完全に理解されていません.
研究 の 目的:
- 低酸素と細胞骨格の改造と癌の転移を結びつける翻訳後のメカニズムを解明する.
- 癌の転移を抑制する新しい治療標的を特定する.
主な方法:
- 低酸素誘導性タンパク質の改変は,生化学的測定と細胞培養モデルを用いて調査された.
- 機能的影響を評価するために遺伝子静止 (shPRMT1) とサイト指向型変異 (vimentin R64K,PRMT1 K134R/K145R) を利用した.
- 異なる酸素条件下でのPRMT1,ヴィメンチン,HDAC8のタンパク質レベルを分析した.
- 三重陰性乳がん (TNBC) の臨床データと相関するヴィメンチンR64非対称性二甲基化 (aDMA) レベル.
- 臨床前の転移モデルでPRMT1阻害剤 (MS023) の有効性を評価した.
主要な成果:
- 低酸素は,K134 / K145でPRMT1の乳化を引き起こし,その活性を増強する.
- 乳酸化されたPRMT1は,R64でのヴィメンチン非対称二メチル化 (aDMA) を触媒化し,フィラメントの組み立てと細胞骨格の改造を促進する.
- PRMT1の阻害またはヴィメンチンR64の変異により,低酸素による移行と転移が取り消された.
- 低酸素はHDAC8 (PRMT1デラクチラゼ) レベルを低下させ,PRMT1の乳化を増加させます.
- PRMT1 K134R/K145R変異体は,ヴィメンチンや救出フィラメント形成に結合できませんでした.
- ヴィメンチンR64aDMA濃度は,TNBCの進行段階と生存率の低下と相関しています.
- PRMT1阻害剤MS023は,最小限の毒性で異種移植における転移を減少させた.
結論:
- 新種の低酸素-PRMT1-ヴィメンチンのシグナル伝達軸は癌の転移を制御する.
- ビメンチンR64 aDMAは転移の主要な媒介体である.
- PRMT1の活性をターゲットにすることで,癌の転移に対する有望な治療戦略を示しています.
関連する概念動画
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Metastasis
5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K


